Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Prostate cancer

Third time lucky? Dutasteride for tertiary prevention of prostate cancer

Nature Reviews Urology volume 10, page 63 (2013)Cite this article

Subjects

Access through your institution
Buy or subscribe

Evidence of the efficacy of dutasteride for prostate cancer prevention is piling up. New research, published in European Urology, suggests that dutasteride treatment can provide protection against disease progression for patients who have undergone radical prostatectomy or radiation therapy for prostate cancer.

Dutasteride (marketed as Avodart® by GlaxoSmithKline [USA]) is a dual 5α-reductase inhibitor (5ARI) that hit the headlines in 2011 when the FDA made the decision not to approve its use for the primary prevention of prostate cancer despite promising results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. After REDUCE came REDEEM (Reduction by Dutasteride of Clinical Progression Events in Expectant Management), which demonstrated a role for dutasteride in the secondary prevention of prostate cancer, owing to its ability to slow disease progression in patients with low-risk prostate cancer under active surveillance.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

  1. Schröder, F. et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placelbo-controlled Avodart after radical therapy for prostate cancer study (ARTS). Eur. Urol. doi:10.1016/j.eururo.2012.11.006

Download references

Authors
  1. Sarah Payton
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Payton, S. Third time lucky? Dutasteride for tertiary prevention of prostate cancer. Nat Rev Urol 10, 63 (2013). https://doi.org/10.1038/nrurol.2012.241

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2012.241

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing